ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals Stock Forecast

Stock Price Forecast

The 9 analysts that cover ANI Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $80.56, which forecasts a 21.8% increase in the stock price over the next year. The lowest target is $65 and the highest is $94.

Price Target: $80.56 (+21.8%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$65	$80.56	$83	$94
Change	-1.72%	+21.80%	+25.49%	+42.12%

Analyst Ratings

The average analyst rating for ANI Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	2	3	3	3	3	4
Buy	4	4	4	4	4	4
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	8	8	8	8	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brandon Folkes HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $84	Strong Buy	Initiates	$84	+27.00%	Jul 10, 2025
Vamil Divan Guggenheim	Guggenheim	Strong Buy Reiterates $86	Strong Buy	Reiterates	$86	+30.03%	May 12, 2025
Gregory Fraser Truist Securities	Truist Securities	Hold Maintains $62 → $65	Hold	Maintains	$62 → $65	-1.72%	Apr 21, 2025
Vamil Divan Guggenheim	Guggenheim	Strong Buy Reiterates $86	Strong Buy	Reiterates	$86	+30.03%	Apr 11, 2025
Oren Livnat HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $94	Strong Buy	Reiterates	$94	+42.12%	Mar 17, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

801.86M

Increased by 30.52%

from 614.38M

Revenue Next Year

861.19M

Increased by 7.40%

from 801.86M

EPS This Year

6.65

from -1.04

EPS Next Year

7.23

Increased by 8.72%

from 6.65

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	208.48M	216.14M	316.39M	486.82M	614.38M	801.86M	861.19M	921.00M
Revenue Growth	0.93%	3.68%	46.38%	53.87%	26.20%	30.52%	7.40%	6.95%
EPS	-1.88	-3.40	-3.05	0.85	-1.04	6.65	7.23	8.38
EPS Growth	-	-	-	-	-	-	8.72%	15.80%
Forward PE	-	-	-	-	-	9.94	9.14	7.90
No. Analysts	-	-	-	-	-	10	10	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	836.4M	910.9M	995.5M
Avg	801.9M	861.2M	921.0M
Low	757.4M	804.0M	830.8M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	36.1%	13.6%	15.6%
Avg	30.5%	7.4%	6.9%
Low	23.3%	0.3%	-3.5%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	6.94	8.48	10.43
Avg	6.65	7.23	8.38
Low	6.26	6.04	6.96

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	27.5%	44.1%
Avg	-	8.7%	15.8%
Low	-	-9.3%	-3.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.